Yangzhou, China

Xinan Jiao

This inventor holds 2 USPTO granted patents. Top assignee: Yangzhou University. Active years: 2023-2025.


% Patents Active = 100.0

Average Co-Inventor Count = 8.9

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Xinan Jiao: Innovator in PCR Detection Technology

Introduction

Xinan Jiao is a prominent inventor based in Yangzhou, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative detection methods. With a total of 2 patents, his work has the potential to impact various applications in medical diagnostics.

Latest Patents

Xinan Jiao's latest patents include a hybridoma cell line that secretes an ActA monoclonal antibody. This invention is crucial for advancing research in immunology. Additionally, he has developed a PCR detection kit designed for rapidly identifying specific serotypes. This kit includes primers for detecting the tcpS gene, which can identify serotypes quickly and efficiently, serving as an auxiliary method for conventional serotyping.

Career Highlights

Xinan Jiao is affiliated with Yangzhou University, where he conducts his research and development activities. His work is characterized by a commitment to enhancing diagnostic techniques through innovative solutions. His contributions have been recognized within the academic community, showcasing his expertise in the field.

Collaborations

Xinan Jiao collaborates with notable colleagues, including Xiang Chen and Zhiming Pan. These partnerships enhance the research environment and foster innovation in their respective fields.

Conclusion

Xinan Jiao's contributions to biotechnology, particularly in PCR detection technology, highlight his role as an influential inventor. His patents reflect a dedication to advancing medical diagnostics, which can lead to significant improvements in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…